Search Results - "Crowley, Jeffrey J."

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa by Kimball, Alexa B, Okun, Martin M, Williams, David A, Gottlieb, Alice B, Papp, Kim A, Zouboulis, Christos C, Armstrong, April W, Kerdel, Francisco, Gold, Michael H, Forman, Seth B, Korman, Neil J, Giamarellos-Bourboulis, Evangelos J, Crowley, Jeffrey J, Lynde, Charles, Reguiai, Ziad, Prens, Errol-Prospero, Alwawi, Eihab, Mostafa, Nael M, Pinsky, Brett, Sundaram, Murali, Gu, Yihua, Carlson, Dawn M, Jemec, Gregor B.E

“…Hidradenitis suppurativa is a painful, chronic inflammatory skin disease. In two double-blind, placebo-controlled trials, treatment with adalimumab resulted in…”
Get full text

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial by Reich, Kristian, Gooderham, Melinda, Thaçi, Diamant, Crowley, Jeffrey J, Ryan, Caitriona, Krueger, James G, Tsai, Tsen-Fang, Flack, Mary, Gu, Yihua, Williams, David A, Thompson, Elizabeth H Z, Paul, Carle

“…Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine…”
Get full text

Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation by Crowley, Jeffrey J, Weinberg, Jeffrey M, Wu, Jashin J, Robertson, Andrew D, Van Voorhees, Abby S

“…Nail psoriasis can be difficult to treat and has a significant effect on quality of life. Relatively few controlled trials evaluating treatments for nail…”
Get more information

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial by Elewski, Boni E., Okun, Martin M., Papp, Kim, Baker, Christopher S., Crowley, Jeffrey J., Guillet, Gérard, Sundaram, Murali, Poulin, Yves, Gu, Yihua, Geng, Ziqian, Williams, David A., Rich, Phoebe A.

“…Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point. This phase 3 trial evaluated the safety and efficacy of…”
Get full text

A brief guide to pustular psoriasis for primary care providers by Crowley, Jeffrey J., Pariser, David M., Yamauchi, Paul S.

“…Pustular psoriasis refers to a heterogeneous group of chronic inflammatory skin disorders that are clinically, histologically, and genetically distinct from…”
Get full text

Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis by Cather, Jennifer C., Crowley, Jeffrey J.

“…Psoriasis is a chronic inflammatory skin disorder, which is associated with a significant negative impact on a patient’s quality of life. Traditional therapies…”
Get full text

A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach by Strober, Bruce, MD, PhD, Berger, Emily, MD, Cather, Jennifer, MD, Cohen, David, MD, MPH, Crowley, Jeffrey J., MD, Gordon, Kenneth B., MD, Gottlieb, Alice, MD, PhD, Horn, Elizabeth J., PhD, Kavanaugh, Arthur F., MD, Korman, Neal J., MD, PhD, Krueger, Gerald G., MD, Leonardi, Craig L., MD, Menter, Alan, MD, Schwartzman, Sergio, MD, Sobell, Jeffrey M., MD, Young, Melodie, MSN, RN, A/GNP-c

“…Clinical trials for systemic psoriasis therapy typically enroll healthy patients and exclude patients with cardiovascular disease, latent tuberculosis, liver…”
Get full text

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab by Blauvelt, Andrew, Muram, Talia M, See, Kyoungah, Mallinckrodt, Craig H, Crowley, Jeffrey J, van de Kerkhof, Peter

“…Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17 A. Examine the efficacy of ixekizumab in clearing psoriasis within…”
Get full text

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study by Crowley, Jeffrey J., Langley, Richard G., Gordon, Kenneth B., Pinter, Andreas, Ferris, Laura K., Rubant, Simone, Photowala, Huzefa, Xue, Zhenyi, Wu, Tianshuang, Zhan, Tianyu, Beeck, Stefan, Shah, Megha, Warren, Richard B.

“…Introduction Patients with moderate-to-severe plaque psoriasis who experience poor clinical outcomes, including patients with obesity or prior treatment, need…”
Get full text

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2 by Strober, Bruce E., Clay Cather, Jennifer, Cohen, David, Crowley, Jeffrey J., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur F., Korman, Neil J., Krueger, Gerald G., Leonardi, Craig L., Schwartzman, Sergio, Sobell, Jeffrey M., Solomon, Gary E., Young, Melodie

“…Introduction Clinicians may be confronted with difficult-to-treat psoriasis cases for which there are scant data to rely upon for guidance. To assist in…”
Get full text

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 by Strober, Bruce E., Clay Cather, Jennifer, Cohen, David, Crowley, Jeffrey J., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur F., Korman, Neil J., Krueger, Gerald G., Leonardi, Craig L., Schwartzman, Sergio, Sobell, Jeffrey M., Solomon, Gary E., Young, Melodie

“…Introduction Traditional clinical trials in psoriasis exclude a significant proportion of patients with complex disease and comorbidities. A consensus panel of…”
Get full text

44134 Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab To Risankizumab by Elewski, Boni, Rich, Phoebe, Langley, Richard G., Shah, Megha, Photowala, Huzefa, Wu, Tianshuang, Patel, Manish, Crowley, Jeffrey J.

Get full text

51109 Efficacy of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in scalp psoriasis by baseline Psoriasis Area and Severity Index (PASI) and baseline body surface area (BSA): A subanalysis of the phase 3 clinical trial data by Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Kisa, Renata M., Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.

Get full text

16480 Characteristics associated with progression of hidradenitis suppurativa: 2-year interim results from the HS UNITE registry by Kimball, Alexa B., Sayed, Christopher, Duan, Yinghui, Longcore, Michelle, Crowley, Jeffrey J.

Get full text

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere) by Simpson, Eric L, Gooderham, Melinda, Wollenberg, Andreas, Weidinger, Stephan, Armstrong, April, Soung, Jennifer, Ferrucci, Silvia, Lima, Renata Gontijo, Witte, Michael M, Xu, Wen, ElMaraghy, Hany, Natalie, Chitra R, Pierce, Evangeline, Blauvelt, Andrew

“…Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe…”
Get more information

13877 Treatment goals of patients with psoriasis as assessed by the Patient Benefit Index: Results of a National Psoriasis Foundation survey by Armstrong, April, Edson-Heredia, Emily, Zhu, Baojin, Shrom, David, Burge, Russel, Bell, Stacie, Crowley, Jeffrey J., Smith, Stacy

Get full text

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data by Blauvelt, Andrew, Sofen, Howard, Lambert, Jo, Merola, Joseph F., Lebwohl, Mark, Hoyt, Kim, Banerjee, Subhashis, Scharnitz, Thomas, Crowley, Jeffrey J.

“…Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with…”
Get full text

Cutaneous gnathostomiasis by Crowley, Jeffrey J, Kim, Youn H

Get full text

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies by Gordon, Kenneth B., Han, Chenglong, Li, Shu, You, Yin, Song, Michael, Fakharzadeh, Steven, Crowley, Jeffrey J., Reich, Kristian

“…Background: Patient-reported and clinician-determined outcomes do not always correlate in clinical trials for psoriasis, even among those with clear skin…”
Get full text

Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE by FRANKEL, Ellen H, STROBER, Bruce E, CROWLEY, Jeffrey J, FIVENSON, David P, WOOLLEY, J. Michael, YU, Elaine B, XIA, Hong A, CHIOU, Chiun-Fang, STEVENS, Seth R

“…Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and…”
Get full text